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5 ABSTRACT: The recent outbreak of coronavirus infectious disease 2019
6 (COVID-19) has gripped the world with apprehension and led to a scare of
7 epic proportions related to its potential to spread and infect humans worldwide. As
8 we are in the midst of an ongoing near pandemic outbreak of COVID-19, scientists
9 are struggling to understand how it resembles and varies with the severe acute
10 respiratory syndrome coronavirus (SARS-CoV) at the genomic and transcriptomic
11 level. In a short time following the outbreak, it has been shown that, similar to
12 SARS-CoV, COVID-19 exploits the angiotensin-converting enzyme 2 (ACE2)
13 receptor to gain entry inside the cells. This finding raises the curiosity of
14 investigating the expression of ACE2 in neurological tissue and the possible
15 contribution of neurological tissues damage to the morbidity and mortality of
16 COIVD-19. Here, we investigate the density of the expression levels of ACE2 in
17 the CNS and the host−virus interaction and relate it to the pathogenesis and
18 complications seen in recent cases of the COVID-19 outbreak. Also, we debate the need for a model of staging COVID-19 based on
19 neurological tissue involvement.
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1. THE NOVEL COVID-19 VIRUS
21 The first reports of a viral infection attracted attention in late
22 December 2019 in Wuhan, the capital of Hubei, China. Later,
23 it was revealed that the virus responsible for causing the
24 infections was contagious between humans. In early January,
25 the terms like “the new coronavirus” and “Wuhan coronavirus”
26 were in common use. On February 11, 2020, a taxonomic
27 designation “severe acute respiratory syndrome coronavirus 2″
28 (SARS-CoV-2) became official in order to refer to the virus
29 strain, that was previously termed as 2019-nCoV and Wuhan
30 coronavirus. Within a few hours on the same day, the WHO
31 officially renamed the disease as COVID-19.
2. THE GENOME OF THE COVID-19 VIRUS
32 The complete genome of COVID-19 virus from Wuhan, China
33 was submitted on January 17, 2020 in the National Center for
34 Biotechnology
1 (NCBI) database, with ID NC_045512. It is a
35 29,903 bp single-stranded RNA (ss-RNA) coronavirus. It has
36 now been shown that COVID-19 is a SARS-like coronavirus
37 that had previously been reported in bats in China.
3. THE TISSUE DISTRIBUTION OF ACE2 IN HUMAN
38ORGANS AND TISSUES
39In order to discover the neurological pathogenic potential of
40COVID-19 and relate it to neurological tissue expression of
41ACE2, data retrieval was done from human protein databases.
42 f1Most of the evidence of ACE2 expression in the brain (Figure
43 f11) comes from literature and mammalian tissue expression
44databases,2 which prompted us to investigate neurotropic
45effects of COIVD-19 and its contribution toward the morbidity
46and mortality of patients with COVID-19.
473.1. Evidence of the Distribution of ACE2 in the
48Human Brain. The brain has been reported to express ACE2
49receptors (Figure 1A, C) that have been detected over glial
50cells and neurons, which makes them a potential target of
51COVID-19. Previous studies have shown the ability of SARS-
52CoV to cause neuronal death in mice by invading the brain via
53the nose close to the olfactory epithelium.3 The contribution of
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54 neural targeting of COVID-19 in patients reported in the
55 recent outbreak remains to be established. In the SARS-CoV
56 infections reported in the past, autopsy findings of the patients
57 have shown the evidence-based presence of SARS-CoV via
58 electron microscopy, immunohistochemistry, and real-time
59 reverse transcription-PCR 3. Patients with acute SARS-CoV
60 illness have also shown the presence of the virus in
61 cerebrospinal fluid. The role of the blood-brain barrier in
62 containing the virus and preventing it from gaining access to
63 the neural tissues needs to be further explored in COVID-19.
64 Recently, a study posted in medRxiv4 has reported neurological
65 manifestations in COVID-19 in the current outbreak that
66 involved 214 patients, of which 78 (36.4%) patients had
67 neurologic manifestations, which affirms our rationale of the
68 neurotropic potential in the COVID-19 virus. Also, a finding
69 published on a patient who had loss of involuntary control over
70 breathing5 during the recent outbreak implores healthcare
71 professionals and clinicians to segregate COVID-19 patients
72 into neurologically affected cases and those who are devoid of
73 neurological deficits.
4. HOST−VIRUS INTERACTION: HOW THE ACE2
74 RECEPTOR IS EXPLOITED BY THE COVID-19 VIRUS
75 TO GAIN ENTRY INSIDE THE HOST CELLS
76 With the mRNA encoding 12 proteins,1 the COVID-19 virus,
77 like SARS-CoV, uses a spike protein S1 that enables the
78 attachment of the virion to the cell membrane by interacting
79 with host ACE2 receptor3,6 (Figure 1C, D). In the later study,6
80 it was shown that the ACE2 binding affinity of the 2019-nCoV
81 spike protein ectodomain was 10−20-fold higher than ACE2
82 binding to SARS-CoV spike protein. A BLASTp search of the
83 COVID-19 RBD subdomain-1 (319th to 591st aa) fetched a
84 spike glycoprotein [bat coronavirus RaTG13] and S1 protein
85 and partial [SARS coronavirus GD322] as a homologue.
86 Pairwise sequence alignments of the three sequences show that
87 though the spike proteins of all three CoV are highly similar,
f2 88 they are not identical (Figure 2A, horizontal arrows), which
89may be the reason for the higher binding affinity of the
90COVID-19 spike protein to the human ACE2 receptor.
91Homology modeling of COVID-19 RBD subdomain-1 (319th
92to 591st aa) in the SWISS-MODEL automated server
93developed a template-based model of the 2019-nCoV
94(COVID-19) spike glycoprotein with a single receptor-binding
95domain up configuration (Figure 2A1) with 100% sequence
96identity. Of the other template-based models developed, it
97expectedly showed a model of the structure of the SARS-CoV
98spike glycoprotein, conformation 2 with about 74% sequence
99identity (Figure 2B, B1), which shows them to be structurally
100and evolutionarily related.
5. A PROPOSED CASCADE OF CEREBRAL
101INVOLVEMENT IN THE COVID-19 INFECTIONS
102The dissemination of COVID-19 in the systemic circulation or
103across the cribriform plate of the ethmoid bone (Figure 1)
104during an early or later phase of the infection can lead to
105cerebral involvement as has been reported in the past for
106SARS-CoV affected patients.3 The presence of COVID-19 in
107general circulation understandably enables them to pass into
108the cerebral circulation (Figure 1A−C) where the sluggish
109movement of the blood within the microcirculation could be
110one of the factors that could facilitate the interaction of the
111COVID-19 virus with ACE2 expressed in the capillary
112endothelium. Subsequent budding of the viral particles from
113the capillary endothelium and damage to the endothelial lining
114can favor viral access to the brain (Figure 1B). Other possible
115mechanisms like the transendothelial migration of the virus can
116also enable virus entry into the brain. Once with the milieu of
117the neuronal tissues, its interaction with ACE2 receptors
118(Figure 1C, D) expressed in neurons2 can initiate a cycle of
119viral budding accompanied by neuronal damage without
120substantial inflammation as has been seen with cases of
121SARS-CoV3 in the past. It is important to mention here that,
122long before the proposed anticipated neuronal damages occur,
123the endothelial ruptures in capillaries accompanied by bleeding
Figure 1. Tissue distribution of ACE2 receptors in humans. Viremia (A) disseminates the COVID-19 virus throughout the body via the
bloodstream (B). Neurotropism may occur via circulation that enables the COVID-19 to reach the brain (C) and bind and engage with the ACE2
receptors (D, blue). COVID-19 docks on the ACE2 via spike protein (D, golden spikes). Shown are lungs, heart, kidneys, intestines, brain, and
testicles that are well-known to express ACE2 receptors and are possible targets of COVID-19.
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124 within the cerebral tissue can have fatal consequences in
125 patients with COIVD-19 infections. The movement of the
126 COVID-19 virus to the brain via the cribriform plate close to
127 the olfactory bulb can be an additional pathway of the virus to
128 affect the brain, and finding of an altered sense of smell or
129 hyposmia in an uncomplicated early stage COVID-19 patient
130 should be investigated thoroughly for CNS involvement.
6. CONCLUSIONS AND FUTURE DIRECTIONS
131 Autopsies of the COVID-19 patients, detailed investigation,
132 and attempts to isolate COVID-19 from the endothelium of
133 cerebral microcirculation, cerebrospinal fluid, glial cells, and
134 neuronal tissue can clarify the role played by this novel
135 COVID-19 coronavirus in the mortalities observed in the
136 recent outbreak. It is important to mention here that though
137 the cerebral damage may complicate a COVID-19 infection, it
138 appears that it is the widespread dysregulation of the
139 homeostasis caused by pulmonary, renal, cardiac, and
140 circulatory damage that proves fatal in COIVD-19 patients.
141 With that being said, a dominant cerebral involvement alone
142 with the potential of causing cerebral edema in COVID-19 can
143 take a lead in causing death long before systemic homeostatic
144dysregulation sets in. Access of COVID-19 to the brain via the
145transcribrial route, as described previously for other CNS
146targeting pathogens,7 appears to be the case in a recently
147reported patient with hyposmia,5 which needs to be further
148investigated by attempting to isolate the COVID-19 virus from
149zones in proximity to the olfactory bulb. The differences in the
150spike proteins of COVID-19 and SARS-CoV (Figure 2A) may
151enable scientists to exploit the contrast in sequences in order to
152identify epitopes in COVID-19 for the development of
153monoclonal antibodies against this virus. With the recent
154COVID-19 outbreak, there is an urgent need to understand the
155neurotropic potential of the COVID-19 virus in order to
156prioritize and individualize the treatment protocols based on
157the predominant organ involvement. Also, a staging system
158based on the severity and organ involvement is needed for
159COVID-19 in order to rank the patients for aggressive or
160conventional treatment modalities.
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Figure 2. (A) Sequence alignment of COVID-19 RBD subdomain-1 (319th to 591st) amino acid (top row) with the bat and SARS-CoV spike
protein (middle and bottom row) that were fetched by BLASTp results of COVID-19 RBD subdomain-1 (319th to 591st) amino acids. Note
horizontal arrows that show areas of contrast. (A1) The homology modeling of COVID-19 RBD subdomain-1 (319th to 591st) amino acid
developed a template (6vsb.1. A)-based model of the 2019-nCoV (COVID-19) spike glycoprotein with a single receptor-binding domain up
configuration. (B). Homology modeling of COVID-19 RBD subdomain-1 (319th to 591st) amino acid developed a template-(5x5b.1.A) based
model of the prefusion structure of SARS-CoV spike glycoprotein in conformation 2 (B1) with 73.96% sequence identity. [Uniprot and SWISS-
MODEL automated server were used for sequence alignments and development of the templates and models, respectively.]
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